Access & reimbursement

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Lenacapavir Turns HIV Prevention Into an Access Stress Test

WHO’s New AMR Plan Makes Stewardship and Access a Single Test

An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer

Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test

Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis

Huntington’s Disease Gets an Oral Target-Engagement Signal

A Urine Test for Alzheimer’s Would Change the Access Conversation

A New CELMoD Raises the Bar in Relapsed Myeloma
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
